Digoxin
- Generic Name
- Digoxin
- Brand Names
- Digox, Lanoxin
- Drug Type
- Small Molecule
- Chemical Formula
- C41H64O14
- CAS Number
- 20830-75-5
- Unique Ingredient Identifier
- 73K4184T59
- Background
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...
- Indication
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...
- Associated Conditions
- Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
- Associated Therapies
- -
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06723691
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Digoxin Medulloblastoma Study
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 23
- Registration Number
- NCT06701812
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸UT Southwestern, Dallas, Texas, United States
A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT06677957
- Locations
- 🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06625827
- Locations
- 🇺🇸
ICON (Site 0001), Lenexa, Kansas, United States
A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06597760
- Locations
- 🇺🇸
Celerion ( Site 0001), Lincoln, Nebraska, United States
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Target Recruit Count
- 30
- Registration Number
- NCT06601517
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Digoxin in NASH (CODIN)
- Conditions
- Interventions
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 144
- Registration Number
- NCT06588699
- Locations
- 🇺🇸
Yale New Haven Health, New Haven, Connecticut, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06575933
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
Bioequivalence Study of Digoxin Tablet in Healthy Subjects
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 80
- Registration Number
- NCT06546215
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 48
- Registration Number
- NCT06503679
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.